This is an excerpt from the press release of Sept 28 99 which you may find in ists entirety at the following location.
biotechltd.com
Robert B. Rieveley, President of Biotech Holdings Ltd., is pleased to announce that Biotech has signed a licensing
agreement for the distribution of Biotech's Adult-Onset Diabetes drug, DIAB II, in Chile. Under the agreement,
Biotech has granted marketing and distribution rights for seven years to Laboratorios SAVAL.
"SAVAL," Mr. Rieveley said, "is one of the most dynamic pharmaceutical companies in Chile. SAVAL, with four
hundred employees, is third in sales in the Chilean pharmaceutical market and second in the number of prescriptions
filled. SAVAL will co-operate with Biotech in the preparation of a registration dossier for DIAB II in Chile. We
believe that SAVAL will prove to be a strong partner for bringing DIAB II to the Chilean market."
In addition to the agreement for Chile, Biotech has licensing agreements for DIAB II in Brazil, Argentina,
Venezuela and Peru and is negotiating with pharmaceutical firms in a number of other Latin American markets. For
North America and Western Europe, Biotech's business plan is based on the Company's continuing discussions with
a number of international pharmaceutical companies to create a relationship that would lead to submitting DIAB II
for approval to the US FDA. |
